Wang Kuo-Chuan, Tang Sung-Chun, Lee Jing-Er, Li Yu-I, Huang Yi-Shuian, Yang Wei-Shiung, Jeng Jiann-Shing, Arumugam Thiruma V, Tu Yong-Kwang
1 Division of Neurosurgery, Department of Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
2 Department of Neurology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
J Cereb Blood Flow Metab. 2017 Feb;37(2):435-443. doi: 10.1177/0271678X16629484. Epub 2016 Jul 20.
We aim to determine the cerebrospinal fluid levels of high mobility group box 1 in subarachnoid hemorrhage patients and to investigate the involvement of the receptor for advanced glycation end products and high mobility group box 1 in the pathogenesis of post-subarachnoid hemorrhage neuronal death. The study included 40 patients (mean age, 59 ± 19 years) with Fisher's grade ≥ III aneurysmal subarachnoid hemorrhage. Cerebrospinal fluid was collected on the seventh day post-hemorrhage. Receptor for advanced glycation end products expression was examined in rat brain tissue following subarachnoid hemorrhage and in cultured neurons exposed to post-subarachnoid hemorrhage cerebrospinal fluid. Therapeutic effects of the recombinant soluble form of RAGE on subarachnoid hemorrhage models were also investigated. The results indicated that a higher level of cerebrospinal fluid high mobility group box 1 was independently associated with unfavorable outcome at three months post-subarachnoid hemorrhage (OR = 1.061, 95% CI: 1.005-1.121). Expression of RAGE increased in post-subarachnoid hemorrhage rat brain cells and in cultured neuron with stimulation of post-subarachnoid hemorrhage cerebrospinal fluid. Administration of recombinant soluble form of RAGE significantly reduced the number of positive TUNEL staining cells in subarachnoid hemorrhage rat and improved cell viability in post-subarachnoid hemorrhage cerebrospinal fluid-treated cultured neurons. Thus, the level of cerebrospinal fluid high mobility group box 1 can be a prognostic indicator for patients with Fisher's grade ≥ III aneurysmal subarachnoid hemorrhage and that treatment with soluble form of RAGE is a novel approach for subarachnoid hemorrhage.
我们旨在测定蛛网膜下腔出血患者脑脊液中高迁移率族蛋白B1的水平,并研究晚期糖基化终产物受体和高迁移率族蛋白B1在蛛网膜下腔出血后神经元死亡发病机制中的作用。该研究纳入了40例Fisher分级≥III级的动脉瘤性蛛网膜下腔出血患者(平均年龄59±19岁)。在出血后第7天收集脑脊液。检测蛛网膜下腔出血后大鼠脑组织及暴露于蛛网膜下腔出血脑脊液的培养神经元中晚期糖基化终产物受体的表达。还研究了重组可溶性晚期糖基化终产物受体对蛛网膜下腔出血模型的治疗效果。结果表明,脑脊液中高迁移率族蛋白B1水平较高与蛛网膜下腔出血后3个月不良预后独立相关(OR=1.061,95%CI:1.005-1.121)。晚期糖基化终产物受体在蛛网膜下腔出血大鼠脑细胞及受蛛网膜下腔出血脑脊液刺激的培养神经元中的表达增加。给予重组可溶性晚期糖基化终产物受体可显著减少蛛网膜下腔出血大鼠中TUNEL染色阳性细胞数量,并改善受蛛网膜下腔出血脑脊液处理的培养神经元的细胞活力。因此,脑脊液中高迁移率族蛋白B1水平可作为Fisher分级≥III级动脉瘤性蛛网膜下腔出血患者的预后指标,且用可溶性晚期糖基化终产物受体进行治疗是一种治疗蛛网膜下腔出血的新方法。